Altre lingue Ultragenyx Pharmaceutical Inc.

Azioni

RARE

US90400D1081

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 18/04/2024			Variaz. 5gg	Var. 1 gen.
43,38 ^USD	-1,65%		-14,44%	-9,28%

15/04	Transcript : Ultragenyx Pharmaceutical Inc. - Special Call
15/04	Ultragenyx Pharmaceutical Inc. annuncia dati intermedi positivi di Fase 1/2 nei pazienti con sindrome di Angelman dopo il trattamento con GTX-102	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	15/04
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology 2024 Annual Meeting	15/04
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	15/04
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	15/04
Sector Update: Health Care Stocks Advance Premarket Monday	15/04
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	15/04
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	15/04
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome	12/04
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting	12/04
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	25/03
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22/03
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	22/03
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing	12/03
Ultragenyx to Participate at Investor Conferences in March	27/02
Ultragenyx Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	26/02
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	23/02
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	23/02
Sector Update: Health Care Stocks Gain Pre-Bell Friday	16/02
Ultragenyx Pharmaceutical Q4 Loss Narrows, Revenue Rises; 2024 Revenue Guidance Set	15/02
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q4 Revenue $127.4M	15/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ultragenyx Pharmaceutical Inc.

Azioni

RARE

US90400D1081

Altre lingue

Filtri